Fate Therapeutics (FATE) Change in Acquisitions & Divestments (2016 - 2026)

Fate Therapeutics has reported Change in Acquisitions & Divestments for 11 years, with the latest figure at $52.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 43.18% year-over-year to $52.6 million; the trailing twelve-month figure through Mar 2026 stood at $272.0 million (down 14.87% YoY), and the FY2025 full-year result was $311.9 million, down 5.68% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $52.6 million, down from $66.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $190.6 million in Q3 2022, with the low at $52.6 million in Q1 2026.
• Historically, Change in Acquisitions & Divestments has averaged $104.7 million across 5 years, with a median of $95.5 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments soared 118.1% — and 2026, when it tumbled 43.18%.
• Fate Therapeutics' Change in Acquisitions & Divestments stood at $166.9 million in 2022, then plunged by 42.78% to $95.5 million in 2023, then plunged by 36.21% to $60.9 million in 2024, then climbed by 8.86% to $66.3 million in 2025, then retreated by 20.75% to $52.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $52.6 million (Q1 2026), $66.3 million (Q4 2025), and $81.4 million (Q3 2025), per Business Quant data.